

For Immediate Release

MedX[®] Health Corp. Completes Public Offering

Mississauga, Ontario, Canada – January 31, 2008 – MedX Health Corp. ("MedX") announces today that it has completed its offering (the "**Offering**") of units of MedX (the "**Units**") by selling a total of 5,110,000 Units at \$0.80 per Unit for total gross proceeds of \$4,088,000. Each Unit is comprised of one common share and one warrant to purchase one common share for \$0.90 for two years. Research Capital Corporation ("**Research**") acted as agent in connection with the Offering. Of the Offering, \$4,000,000 was raised through a public offering conducted pursuant to a preliminary prospectus of MedX dated November 2, 2007 and a final prospectus of MedX dated January 10, 2008 filed with the securities commissions in British Columbia, Alberta, Manitoba and Ontario, and \$88,000 was raised through private placement in other jurisdictions. The Units issued in the private placement are subject to a four-month hold period expiring June 1, 2008.

Immediately prior to the completion of the Offering, MedX issued a total of 1,824,489 units to certain creditors to settle a total of \$1,459,592 of outstanding debt. These units have the same terms as the Units, except that they are subject to a four-month hold period expiring June 1, 2008. In addition, the holder of a non-interest bearing convertible note in the amount of \$56,250 converted the note into 112,500 common shares immediately prior to the completion of the Offering.

Prior to the closing of the Offering, MedX had 15,171,937 common shares outstanding. After the Offering, MedX has 22,218,926 common shares outstanding.

Research and its sub-agents received a commission of \$367,920 and compensation options to acquire an aggregate of 511,000 Units at \$0.80 per Unit for two years. Research also received reimbursement of its expenses including legal expenses from MedX.

MedX has received conditional approval from the TSX Venture Exchange for a Tier 2 listing of its common shares and common shares underlying convertible securities. MedX anticipates that listing will be subject to MedX fulfilling all conditions set out in the conditional approval.

The net proceeds of the Offering will be used for expansion of distribution network, marketing program, product development for new dental, rehabilitation and wound care products, research and development for wound care study and for working capital purposes.

For further information, please contact:

Phil Passy
President and Chief Executive Officer
Phone: (905) 826-0766
Email: investor@medxhealth.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.